Table 5. Associations of smaller changes in conventional lipid measures with subsequent risk of incident EDS (n=3919).
| Conventional lipid measure | s.d. | HR (95% CI) | P |
|---|---|---|---|
| Absolute change, mg dl−1 | |||
| Total cholesterol | 31.6 | 0.89 (0.80–1.00) | 0.048 |
| LDL cholesterol | 29.0 | 0.90 (0.81–1.00) | 0.06 |
| HDL cholesterol | 8.2 | 1.02 (0.93–1.12) | 0.69 |
| Non-HDL cholesterol | 31.5 | 0.89 (0.79–0.99) | 0.04 |
| Triglycerides | 52.4 | 0.95 (0.86–1.04) | 0.28 |
| Relative change, % | |||
| Total cholesterol | 15.9 | 0.88 (0.80–0.99) | 0.03 |
| LDL cholesterol | 25.8 | 0.92 (0.85–1.00) | 0.054 |
| HDL cholesterol | 16.0 | 1.01 (0.92–1.10) | 0.85 |
| Non-HDL cholesterol | 21.9 | 0.90 (0.81–0.99) | 0.03 |
| Triglycerides | 43.0 | 0.92 (0.84–1.01) | 0.08 |
Abbreviations: CI, confidence interval; EDS, elevated depressive symptoms; HDL, high-density lipoprotein; HR, hazards ratio; LDL, low-density lipoprotein.
HR is expressed in terms of per s.d. decrease in the change of each lipid measure from baseline visit 1 to visit 3.
Data were adjusted for age, age-squared, sex (as both time-independent and -dependent variables), race/ethnicity, education, smoking, pack years of smoking, total gross family income, marital status, body mass index, heart rate, hypertension, self-reported cancer, interleukin-6, estimated glomerular filtration rate, corresponding lipid levels at baseline visit 1, HDL cholesterol, LDL cholesterol (except for total cholesterol and non-HDL cholesterol) and triglycerides at visit 1, history of lipid-lowering medication usage at visits 1 and 3 (‘no use at both visits', ‘use at visit 1, but no use at visit 3', ‘no use at visit 1, but use at visit 3' and ‘use at both visits'), time between visit 1 and visit 3, and change in weight from visit 1 to visit 3.